30 likes | 43 Views
The In vitro toxicology testing market was valued at USD 5.99 Billion in 2016 and is expected to grow at a CAGR of 6.6% during the forecast period to reach to USD 8.74 Billion by 2022
E N D
In Vitro Toxicology Testing Market worth 8.74 Billion USD by 2022 www.MarketsandMarkets.com
According to a new market research report "In Vitro Toxicology Testing Market by Products (Assays) & Services, Toxicity Endpoints & Tests (ADME, Skin, Genotoxicity, Organ Toxicity), Technology (Cell-based, HTS), Method (Cellular Assays, Ex-Vivo), Industry (Pharmaceutical, Cosmetics) - Forecast to 2022", The in vitro toxicology testing market is expected to reach USD 8.74 Billion by 2022 from an estimated USD 6.34 Billion in 2017, at a CAGR of 6.6%. www.MarketsandMarkets.com
Browse 139 Market Data Tables and 32 Figures spread through 253 Pages and in-depth TOC on "In Vitro Toxicology Testing Market by Products (Assays) & Services, Toxicity Endpoints & Tests (ADME, Skin, Genotoxicity, Organ Toxicity), Technology (Cell-based, HTS), Method (Cellular Assays, Ex-Vivo), Industry (Pharmaceutical, Cosmetics) - Forecast to 2022" • https://www.marketsandmarkets.com/Market-Reports/in-vitro-toxicology-testing-market-209577065.html • Early buyers will receive 10% customization on reports. • The key factors driving the growth of this market include opposition to animal testing, growing demand for in vitro technology in the European market, new and promising technologies, and increasing R&D expenditure to detect toxicity at an early stage. • By Toxicity Endpoints and Tests, ADME hold the largest market share in 2017 • Cell culture technology to hold the largest market share in 2017 • US expected to hold the largest share of the in vitro toxicology testing market in 2017 • The major players in the global in vitro toxicology testing market include Cyprotex (An Evotec AG subsidiary, Germany), Covance (A Laboratory Corporations of America Holding’s subsidiary, US), Eurofins Scientific SE (Luxembourg), GE Healthcare (US), Thermo Fisher Scientific (US), SGS SA (Switzerland), Promega Corporation (US), Merck KGaA (Germany), Charles River Laboratories, Inc. (US), and Lonza Group Ltd. (Switzerland), among others.